A) <90 mmHg B) <110 mmHg C) <80 mmHg D) <100 mmHg
A) 0.14% B) 0.50% C) 0.01% D) 1.4%
A) 16% B) 69% C) 50% D) 96%
A) 100 μg/L B) 1000 μg/L C) 50 μg/L D) 500 μg/L
A) Age multiplied by 10 μg/L B) Age multiplied by 5 μg/L C) Age plus 500 μg/L D) Age divided by 10 μg/L
A) 5% to 15% B) 69% to 84% C) 50% to 60% D) 16% to 47%
A) Right heart catheterization B) Leg ultrasound C) CT pulmonary angiography D) Erythrocyte sedimentation rate
A) It cannot rule out PE B) It is rarely available C) It is highly invasive D) It is less accurate than a blood count
A) It is significantly inferior B) It is less sensitive C) It is non-inferior D) It is much more expensive
A) It has 100% specificity B) It requires right heart catheterization C) It is always done before D-dimer D) It may identify other lung disorders
A) 50% B) 83% C) 69% D) 96%
A) It has limited sensitivity B) It is too expensive C) It has 0% specificity D) It requires contrast agent
A) To measure lung function B) To provide evidence for the need for imaging C) To definitively confirm PE D) To replace the need for CTPA entirely
A) Full blood count and clotting status B) D-dimer only C) Troponin only D) Blood pressure only
A) Age bias B) Incorporation bias C) Measurement bias D) Selection bias
A) 69% B) 96% C) 83% D) 50%
A) Blood glucose levels B) Red blood cell count C) Factor V Leiden mutation D) Vitamin D levels
A) Greater than 120 beats per minute B) Exactly 150 beats per minute C) Between 100 and 110 beats per minute D) Less than 100 beats per minute
A) Between 85% and 90% B) More than 94% C) Less than 80% D) Exactly 90%
A) No leg swelling B) No history of surgery C) Estrogen use D) No coughing up blood
A) To diagnose lung cancer B) As a screening test for everyone C) As a confirmatory test D) To replace the need for clinical history
A) 10% B) 41% C) 80% D) 96%
A) Clinical reasoning B) Patient preference alone C) The time of day D) Hospital policy only
A) No previous blood clots B) Age less than 50 C) A history of trauma in the last year D) No leg swelling
A) Portal vein thrombosis B) Distal calf DVT C) Iliofemoral DVT D) Superficial venous thrombosis
A) Athletes with chronic dehydration B) Elderly women with cancer C) Young men without significant risk factors D) Children with genetic disorders
A) Chronic venous insufficiency B) Arterial thrombosis C) Venous thromboembolism D) Pulmonary hypertension syndrome
A) The clotting cascade B) Virchow's triad C) The VTE framework D) The hypercoagulable model
A) Tonsillectomy B) Orthopedic surgery at or below the hip C) Dental surgery D) Ocular surgery
A) Protein S deficiency B) Protein C deficiency C) Factor V Leiden D) Antiphospholipid syndrome
A) Paroxysmal nocturnal hemoglobinuria B) Nephrotic syndrome C) Antiphospholipid syndrome D) Protein C deficiency
A) They cause systemic dehydration B) They stimulate procoagulant secretion C) They decrease the blood viscosity D) They cause endothelial injury
A) Low altitude living B) High-fiber diet C) Frequent exercise D) Prolonged bed rest
A) White blood cell count B) Liver function test C) D-dimer D) Troponin test
A) Aspirin B) Warfarin C) Acetaminophen D) Ibuprofen
A) Temporary vena cava filter B) Blood transfusion C) Chest tube insertion D) Lung transplant
A) Hemoptysis B) Cyanosis C) Dyspnea D) Tachypnea
A) Heparin B) Direct-acting oral anticoagulants C) Warfarin D) Tissue plasminogen activator
A) Less than 1% B) About 15% C) Nearly 90% D) 50%
A) Philip Steven Wells B) The 64-slice MDCT researchers C) The Geneva rule group D) The PIOPED investigators
A) High probability B) Moderate probability C) Confirmed PE D) Low probability
A) 1.5 points B) 3.0 points C) 2.0 points D) 1.0 points
A) 1.0% B) 97.4% C) 5.0% D) 21.9%
A) PIOPED recommendation B) Wells score C) Geneva rule D) PERC rule
A) Pregnant patients B) Elderly patients C) Patients with high blood pressure D) Patients with chronic obstructive pulmonary disease
A) Chest X-ray B) Planar two-dimensional imaging C) Fluoroscopy D) SPECT
A) S1Q3T3 B) Left bundle branch block C) Prolonged PR interval D) ST elevation in V5-V6
A) Inverted T waves in V1-V4 B) Atrial fibrillation C) Complete heart block D) Sinus tachycardia
A) Normal sinus rhythm B) Atrial fibrillation C) Sinus bradycardia D) QRS narrowing
A) Antibiotic therapy B) Thrombolysis C) Diuretic monotherapy D) Beta-blocker administration
A) White blood cell count B) Creatinine C) Brain natriuretic peptide D) C-reactive protein
A) Determining lung volume B) Diagnosing pneumonia C) Checking for pleurisy D) Prognosis assessment
A) Homan's sign B) Virchow's sign C) Trousseau's sign D) McConnell's sign
A) 50% B) 77% C) 25% D) 94%
A) Only if they are asymptomatic B) Only if they are under 18 years old C) Yes D) No
A) Albumin B) Hemoglobin C) Glucose D) Troponins
A) Long-term aspirin therapy B) Surgical removal of the embolus C) Bed rest and elevation D) Anticoagulant therapy
A) Heparin B) Warfarin C) Fondaparinux D) Aspirin
A) Dabigatran B) Aspirin C) LMWH D) Warfarin
A) 1 week B) 10–12 months C) 1 month D) 3–6 months
A) 1 month B) 6 months C) 2 years D) 10 years
A) Itching B) Hypotension C) Mild headache D) Increased appetite
A) 5% B) 10% C) 50% D) 26%
A) Cambridge Medical Center B) Oxford University Hospital C) Bristol Royal Infirmary D) London General Hospital
A) COPD B) Allergies C) Thyroid disease D) Type 1 diabetes
A) Old technology detected only severe PEs B) The data was fabricated C) The sample size was too large D) The patients were all children
A) Elevated cardiac enzymes B) Low hemoglobin C) High blood glucose D) Increased white blood cell count
A) Fibrinolysis B) Surgery C) Radiation D) Osmosis
A) 15 B) 5 C) 10 D) 11
A) 40,000 B) 100,000 C) 10,000 D) 250,000 |